Pharmalot

Pharmalot By Ed Silverman

Former Genentech scientist convicted of stealing trade secrets given to former JHL Biotech execs

Pharmalot By Ed Silverman

Purdue reaches deal with 15 states in a significant step toward bankruptcy plan approval

Pharmalot By Ed Silverman

Pharmalittle: In rare move, FDA revises label for Biogen Alzheimer’s drug; former compounding exec gets added jail time

Pharmalot By Ed Silverman

Pharmalittle: Another lawmaker calls for probe of FDA approval of Alzheimer’s drug; Roche urged to lower price of Covid-19 therapy

Pharmalot By Ed Silverman

Doctors Without Borders urges Roche to cut price of drug now recommended for Covid-19

Pharmalot By Ed Silverman

Pharmalittle: Purdue wants to shower employees with $34.7 million in bonuses; Emergent faces shareholder suits

Pharmalot By Ed Silverman

Regulators in many European countries fail to ensure clinical trial data are available

Pharmalot By Ed Silverman

Purdue wants to shower employees with nearly $35 million in different kinds of bonuses

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Glaxo rejects hedge fund’s demands; FTC approves resolutions to probe pharma repeat offenders

Pharmalot By Ed Silverman

U.S. cancer drug prices were higher at launch than in three European countries — and just kept climbing

Pharmalot By Ed Silverman

Pharmalittle: Glaxo under more pressure from activist investor; WHO urges Gilead to lower price of black-fungus drug

Pharmalot By Ed Silverman

Mallinckrodt cleared to sell a rare disease drug to a startup, but parents worried over ongoing access

Pharmalot By Ed Silverman

Pharmalittle: Most doctors disagree with FDA approval of the new Alzheimer’s drug; women underrepresented in life sciences C-suites

Pharmalot By Ed Silverman

Revised analysis nudges up cost-effective price for Biogen’s Alzheimer’s drug to $3,000 to $8,400 a year

Pharmalot By Ed Silverman

Poll: Most neurologists and primary care doctors disagree with FDA’s approval of Alzheimer’s drug

Pharmalot By Ed Silverman

Pharmalittle: How Biogen and FDA formed a back channel to push an Alzheimer’s drug; Sanofi to dive into mRNA vaccine development

Pharmalot By Ed Silverman

‘This is not enough’: Walmart’s plan to sell another private label insulin is met with skepticism

Pharmalot By Ed Silverman

Will Gilead’s early data for its CAR-T therapy give it an edge over Bristol Myers?

Pharmalot By Ed Silverman

Pharmalittle: Biogen Alzheimer’s drug will cost Medicare how much? Intellia data suggest a first for genome editing

Pharmalot By Ed Silverman

Johnson & Johnson agrees to pay $230 million to settle opioid case in New York

Pharmalot By Ed Silverman

In an about-face, Health Canada allows a controversial rare disease drug back on the market

Pharmalot By Ed Silverman

Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows

Pharmalot By Ed Silverman

As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat black fungus in recovering patients

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: Sanofi dengue vax endorsed by expert CDC panel; Pfizer recalls Chantix as it tests for possible carcinogens

Pharmalot By Ed Silverman

Will FDA quickly review a Lilly drug to alleviate cost concerns for Alzheimer’s treatments?

Pharmalot By Ed Silverman

Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens

Pharmalot By Ed Silverman

Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism